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This paper describes a highly specific and sensitive radioimmunoassay for a-human atrial natriuretic factor 
(a-hANF), the C-terminal 28-amino-acid residue portion of human prepro-ANF in human plasma. A novel 
extraction and prepurification procedure allowed for detection of levels of immunoreactive-a-hANF as low 
as 0.5 fmol/ml. In normotensive subjects, levels in the range l-23 fmol/ml (mean = 8.9 fmol/ml) were found. 
Combined gel permeation and HPLC analysis demonstrated that this ir-a-hANF was comprised virtually 
exclusively ofauthentic 28-residue a-hANF. No evidence for occurrence of larger precursor forms in human 
plasma was acquired. A heterogenous group of hypertensive patients displayed considerably higher levels 
(mean = 62.2 fmol/ml), of interest in view of the hypotensive properties of ANF. 
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1. INTRODUCTION 
The atrial natriuretic factors (ANF) comprise a 
family of naturally occurring peptides possessing 
natriuretic, diuretic [l] and smooth muscle relax- 
ant properties [2]. They were originally isolated 
and characterized from rat heart [3-51 and their 
presence in the plasma of the rat [6,7] has been 
established. Recently, it proved possible to 
demonstrate their occurrence in human heart [8], 
but as yet no method allowing for their reliable 
determination and characterization in human 
plasma is available. This would appear to be of 
particular importance since, via the systemic cir- 
culation, they may play a role in modulation of, 
for example, extracellular volume or electrolyte 
balance and may be involved in the 
Abbreviations: ir, immunoreactive; RIA, radioim- 
munoassay; HPLC, high-performance liquid chroma- 
tography; HPGPC, high-performance g l permeation 
chromatography; cu-hANF, a-human ANF; cu-rANF, cy- 
rat ANF; AP I,II,III, atriopeptin I,II,III 
pathophysiology of conditions such as primary or 
secondary hypertension. In addition, measurement 
of their levels in plasma would allow for the 
monitoring of their release and of the functional 
activity of ANF systems. We have, therefore, 
developed a method for the extraction, determina- 
tion and characterization of c+hANF, the C- 
terminal 28-amino-acid residue portion of the 
human precursor, prepro-ANF [9], in human 
plasma and initiated studies involving the evalua- 
tion of the levels of this in various pathological 
states. 
2. MATERIALS AND METHODS 
2.1. Generation of &ANF-directed antibodies 
Human IY-ANF (Nova Biochem, Switzerland) 
was covalently conjugated to bovine thyroglobulin 
employing carbodiimide as a coupling agent as in 
[lo]. A conjugate fraction was emulsified with an 
equal volume of complete Freund’s adjuvant and 
2 ml emulsion (equivalent o 800 pg cu-hANF) was 
injected intradermally at multiple sites on the back 
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of 3 male New Zealand rabbits. At intervals of 4 
weeks, animals were boosted with 2OOag ANF 
conjugate emulsified in Freund’s incomplete adju- 
vant. 4 weeks following booster, serum was col- 
lected, divided and stored at -30°C. 
2.2. Preparation of ‘251-a-hANF 
1 mCi 125 I in a volume of 10~1 was added to 
5 rg a-hANF in 50 pl of 0.5 M sodium phosphate 
buffer, pH 7.2. The reaction was initiated by the 
addition of 10~1 chloramine T solution (2O/cg in 
0.05 M sodium phosphate buffer, pH 7.4). The 
mixture was shaken for 30 s and the reaction 
stopped by 10 ,ul sodium metabisulfite solution 
(20rg in 0.05 M sodium phosphate buffer, pH 
7.4). Iodinated cy-hANF was purified by gel filtra- 
tion on a 1 x 30 cm column of Bio-Gel P4 
(pretreated with 1% bovine serum albumin and 
eluted with 0.1 M acetic acid). l-ml fractions were 
collected into polypropylene tubes to which 100 ~1 
RIA buffer were added to minimize adsorbance of 
the peptide to the tube walls. Fractions were frozen 
and stored at -30°C. 
2.3. Radioimmunoassay for cy -hANF 
RIA buffer (300~1 containing 0.02 M sodium 
phosphate, 0.15 M NaCl, 0.01% bovine serum 
albumin, 0.1% gelatin, 0.01% thiomerosal, 0.1% 
Triton X-100) were mixed with 50~1 of a-hANF 
standards or samples in 1.5 ml Eppendorf plastic 
vials. lOO/cl of antiserum ‘Toni II’ were added to 
yield a final antibody dilution of 1: 35000. The 
reaction was initiated with 1251-(Y-hANF in 50~1 
RIA buffer and allowed to incubate at 5°C for 
12-16 h. Separation of bound and free hormone 
was achieved by addition of 500~1 of a mixture 
containing 1% charcoal and 0.5% bovine serum 
albumin in RIA buffer without addition of Triton 
X-100. The suspension was left for 10 min, then 
centrifuged for 3 min. 800~1 supernatant was 
counted in a y-counter. 
2.4. Collection of plasma samples 
Peripheral blood was drawn into pre-cooled 
20 ml syringes containing 500 KIU/ml aprotinin. 
Blood was transferred to pre-cooled polystyrene 
tubes containing 1 mg/ml sodium EDTA. The 
tubes were centrifuged at 4°C for 20 min at 
5000 rpm, and the plasma removed and stored at 
- 70°C. In a preliminary study, blood was drawn 
58 
from 17 hypertensive patients displaying elevated 
blood pressure at the time of examination and 13 
normotensive control subjects. 
2.5. Plasma extraction 
Human plasma and rat plasma interfered 
nonspecifically with the RIA yielding falsely high 
levels of ‘immunoreactivity’. Therefore, we 
developed an extraction method to exclude 
nonspecific interference and allow for the pre- 
purification of ir-cr-hANF. Amberlite XAD-2 ad- 
sorbent resin (particle size 0.3-1.0 mm; Serva, 
Heidelberg) was found to be most satisfactory, 
since it adsorbed more than 98% of synthetic cy- 
hANF from plasma, independent of concentration 
in the range 6-200 fmol/ml. 9 g was packed into 
lo-ml plastic columns, 5 ml plasma was loaded on- 
to the column, the columns rinsed with distilled 
water and ANF eluted with 9 ml of 55% 
acetonitrile in 0.1 M acetic acid. Eluates were 
lyophilized and either redissolved in buffer for 
RIA or subjected to HPGPC and subsequent 
HPLC analysis. 
2.6. HPGPC and reverse-phase HPLC 
HPGPC of plasma extracts was performed on 2 
serially connected TSK-125 Bio Sil columns (7.5 x 
600 mm) (Bio-Rad, Richmond, CA) eluted with 
0.09% trifluoroacetic acid (TFA), containing 
0.005 M NazS04 plus 0.002 M NaHzP04 and 30% 
acetonitrile, as a solvent. The flow rate was 
0.8 ml/min. Aliquots from column fractions were 
analyzed for ir-cu-hANF as shown in fig.2. 
Thereafter, the immunoreactive peak co-eluting 
with synthetic standard was re-chromatographed 
on a Waters Cl8 FBondapack reverse-phase col- 
umn (3.9 x 300 mm) and fractions assayed for (Y- 
hANF immunoreactivity (fig.3). The HPLC col- 
umn was eluted with 0.1% TFA and a linear gra- 
dient of acetonitrile from 10 to 35%. 
3. RESULTS 
A typical standard curve for a-hANF and 
crossreactivities of the Toni II antiserum to a- 
rANF, AP I,II,III are shown in fig.1. The serum 
displays a high avidity for a-hANF. The detection 
limit of the RIA (90070 displacement) was 
7 fmol/tube. The antiserum also recognizes cy- 
rANF and AP III with 50 and 70% lower avidity, 
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Fig.1. Typical standard curve of a-hANF and cross-reactivities of ru-rANF and AP I, II, III in the RIA. 
respectively. C-terminally abbreviated fragments, 
AP I and II, crossreact with the antiserum by 1 
and 2%) respectively. Thus, for recognition by the 
Toni II antiserum an intact C-terminus is essential. 
Toni II showed negligible crossreactivity 
(<O.OOl @Jo) with &endorphin, dynorphin B, 
dynorphin A, dynorphin Al-s, a-neo-endorphin, 
amidorphin, bovine-adrenal-medullary-22-peptide, 
N-acetyl-,&endorphin, Leu-enkephalin, ACTH, 
arg’-vasopressin, oxytocin, angiotensin II, Met- 
Lys-bradykinin, and dopamine. To preclude false 
positive values due to tracer degradation in the 
RIA incubation, the complete plasma extract RIA 
mixture was subjected to reverse-phase HPLC on 
a Cl8 PBondapack column. All radioactivity 
eluted in the position of the non-incubated tracer. 
Since even a few microliters of un-extracted 
plasma in the RIA mixture caused gross, non- 
parallel inhibition of tracer binding, all plasma 
samples were extracted prior to RIA. As extraction 
by adsorption to XAD 2-adsorbent resins was per- 
formed with 5 ml plasma the detection limit was 
-1.4 fmol/ml plasma. If necessary, the method 
allows for extraction of up to 15 ml plasma, 
yielding an effective increase in sensitivity such 
that 0.5 fmol/ml plasma can be detected. The effi- 
ciency of extraction (recovery) as determined by 
the addition of synthetic standards to 5-ml plasma 
aliquots was greater than 98% and independent of 
concentration in the range 6-200 fmol/ml. Levels 
of ir-cr-hANF in normotensive subjects (n = 13) 
were found to be 8.9 + 2.4 fmol/ml (mean f SE). 
In contrast, considerably higher levels were seen in 
hypertensive patients (62.2 f 19.7 fmol/ml, 
mean + SE, n = 17) (P I 0.02, Student’s two- 
tailed t-test). 
4. DISCUSSION 
This paper describes the development of an RIA 
for cu-hANF which, in conjunction with a novel ex- 
traction and purification procedure employing ad- 
sorbent resins, allows for the detection of ire- 
hANF in human plasma in concentrations as low 
as 0.5 fmol/ml. This very high sensitivity appears 
to be particularly crucial in view of the very low 
levels, in the range l-23 fmol/ml, of ir-cu-hANF 
which were found in normotensive individuals. 
Miyata et al. [l l] have, in fact, reported con- 
siderably higher levels in unextracted plasma. 
However, as for a great variety of peptide hor- 
mones [10,12,13] our studies suggest that these 
reflect non-parallel inhibition of tracer binding by 
plasma in the RIA for cu-hANF, yielding 
misleadingly high values. Indeed, it appears that 
extraction is an essential step for the reliable deter- 
mination of ir-cu-hANF in human plasma. Analysis 
of plasma extracts on HPGPC (fig.2) and subse- 
quent HPLC (fig.3) revealed that ir-cu-hANF in 
human plasma is comprised, virtually exclusively, 
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Fig.2. Mr pattern of ir-tu-hANF in human plasma 
extracts on a TSK-125 Bio Sil HPGPC system. Fraction 
ahquots were assayed for &rANF immunoreactivity. 
Columns were calibrated with V, = bovine serum 
albumin, VT = Leu-enkephalin and a series of opioid 
peptides and synthetic u-hANF. 
of the authentic C-terminal 28-amino-acid residue 
portion of the precursor, human prepro-ANF [9]. 
Although the Toni II antiserum would appear 
capable of recognizing related ANF peptides with 
an intact C-terminus, no such cu-hANF-related 
fragments were seen: however, the presence of 
small amounts of these below the limit of assay 
sensitivity cannot be discounted. Notwithstanding 
the occurrence of the N-terminally extended frag- 
ment containing mu-hANF (y-hANF, the 126- 
amino-acid residue peptide) in human hearts [ 141, 
we detected neither this nor other larger precursor 
forms in human plasma upon chromatography. 
This is in good agreement with a recent study in the 
rat in which it was indicated that the rat heart does 
contain high-M forms but secretes exclusively 
ANFs of 20-35 amino acid residues [15]. The 
development of such a highly sensitive assay al- 
lowing for the detection of authentic a-hANF in 
human plasma renders the evaluation of any pos- 
sible change in cu-hANF in pathological states 
feasible. In view of the ability of exogenously 
administered ANFs to lower the blood pressure 
[16], it is of interest that in a heterogenous group 
of hypertensive patients levels of ir-cu-hANF in 
plasma were higher than in normotensive subjects. 
The mechanism underlying this increase is at 
present unclear: the attractive possibility that it 
reflects a (compensatory) accelerated release of 
ANF evidently requires further evaluation. Never- . 
theless, by use of this assay, it is clearly possible to 
evaluate the patterns of release of ANF and its 
molecular distribution in various forms of hyper- 
tension and cardiovascular disease. We are cur- 
rently addressing these and other questions of 
clinical relevance. 
cf-h-ANF 
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Fig.3. HPLC analysis of a-hANF from human plasma following HPGPC (see fig.2). The immunoreactive peak co- 
eluting with synthetic cr-hANF on the HPGPC system was re-chromatographed on a Waters HPLC Cl8 reverse-phase 
column, and then re-assayed for a-hANF immunoreactivity. 
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